Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain scans reveal Ketamine's secret against suicidal thoughts?

NCT ID NCT07139106

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study looks at how ketamine, a drug already used for depression, might reduce suicidal thoughts by affecting stress-related brain pathways. Researchers will give 12 adults with major depressive disorder a single ketamine infusion, then use smartphone tracking and PET brain scans to monitor changes. The goal is to understand the biological link between stress and suicidal thinking, not to test ketamine as a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ketamine hydrochloride infusion
What this could lead to
If successful, this could reveal how ketamine reduces suicidal thoughts, pointing toward better treatments for depression-related suicide risk.
What could go wrong
This is a very small early-phase study with only 12 participants, so results may not apply broadly. It focuses on understanding brain mechanisms, not proving a treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 12 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 59 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * DSM5 unipolar major depressive episode * Persons of child-bearing potential must agree to use an acceptable method of birth control throughout the study. Exclusion Criteria: * Current or past ketamine abuse or dependence ever (lifetime) * Any medical contraindication to ketamine, including prior ineffective trial of or medically significant adverse reaction to ketamine. * Clinically significant EKG abnormality in terms of ketamine administration (e.g., Ventricular tachycardia, evidence of myocardial ischemia, symptomatic bradycardia, unstable tachycardia, second degree (or greater) AV block). * Lifetime schizophrenia, schizoaffective illness, bipolar disorder, current psychotic depression; mild drug or alcohol use disorder in past 2 months; moderate or severe drug or alcohol use disorder in past 6 months; suicidal ideation with plan and/or intent within 6 months; suicide attempt in the past month. * A first-degree family history of schizophrenia if the subject is less than 33 years old (mean age of onset for schizophrenia plus two standard deviations). * Current or recent use of antidepressants within 14 days or benzodiazepines within 1 day. Use of fluoxetine or other long-acting antidepressant within 6 weeks. * Current or recent use of medications known to affect brain biology of interest such as competing for binding sites of PET tracer within 1 month. * Uncontrolled moderate or severe hypertension (≥160 mmHg systolic or ≥100 mmHg diastolic\[41\]), history of Raynaud's phenomenon, seizures, an open cut, sore, or bone fracture on or near the hands to be used for the cold pressor test. * Use of more than incidental NSAIDs (including aspirin), anti-inflammatories, immune suppressants or other pain medications. * Significant active physical illness, particularly if it may affect the brain biology being studied; including chronic pain syndrome and medically compromising eating disorders or epilepsy. * Lacks capacity to consent * Aggressive behavior that is a significant threat to others such as physically assaultive behavior (in the last month). * Pregnancy, abortion or miscarriage in the previous two months or plans to conceive during the course of study participation. * Currently lactating * Previous head injury with evidence of cognitive impairment. Subjects who endorse a history of prior head trauma and score 1.5 standard deviations below the mean on Trail-making A or B will be excluded from study participation. * Any condition or material in the body that is a contraindication for MRI procedures. * Current, past or anticipated exposure to radiation except if the exposure was at our PET center where the precise exposure is known * ECT within past 6 months * For A-Line Subjects: Unstable relevant medical condition (i.e., condition not adequately stabilized for 3 months). Including bleeding disorders, the need to take medications that affect blood clotting, and certain platelet and hemoglobin cutoffs * Blind or with visual impairment that cannot be corrected with corrective lenses (glasses or contact lenses) * No emergency contact

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder (MDD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • New York State Psychiatric Institute

    New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.